Literature DB >> 2113077

Granulocyte-macrophage and macrophage colony-stimulating factors activate intramacrophage killing of Leishmania mexicana amazonensis.

J L Ho1, S G Reed, E A Wick, M Giordano.   

Abstract

Leishmania organisms are important pathogens, causing diseases worldwide. Standard therapies are often toxic and are not always effective. The effect of recombinant human granulocyte-macrophage and macrophage colony-stimulating factors (GM-CSF and M-CSF) on intramacrophage survival of Leishmania mexicana amazonensis (Lma) were compared with those of interferon-gamma (IFN-gamma). Macrophages previously infected with Lma were treated with or without GM-CSF and M-CSF. Compared with no cytokine treatment, treatment with GM-CSF (0.1-100 ng/ml) or M-CSF (1:3.5 X 10(6) - 1:3.5 X 10(3) dilutions) caused a significant dose-dependent reduction in intracellular parasites, 427 +/- 20 (mean +/- SE) Lma/100 macrophages. GM-CSF or M-CSF in combination with IFN-gamma resulted in more effective inhibition of intracellular parasites. Thus, the cytostatic activity appears to require interaction between cytokines, macrophages, and amastigotes. These cytokines are potential therapeutic agents for visceral leishmaniasis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2113077     DOI: 10.1093/infdis/162.1.224

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  13 in total

1.  Recombinant Granulocyte-Macrophage Colony-Stimulating Factor (rGM-CSF) : A Review of its Pharmacological Properties and Prospective Role in the Management of Myelosuppression.

Authors:  Susan M Grant; Rennie C Heel
Journal:  Drugs       Date:  1992-04       Impact factor: 9.546

2.  Effects of granulocyte-macrophage colony stimulating factor (GM-CSF) in vivo on cytokine production and proliferation by spleen cells.

Authors:  S Khatami; E Brummer; D A Stevens
Journal:  Clin Exp Immunol       Date:  2001-08       Impact factor: 4.330

3.  Granulocyte-macrophage colony-stimulating factor in combination with pentavalent antimony for the treatment of visceral Leishmaniasis.

Authors:  R Badaró; C Nascimento; J S Carvalho; F Badaró; D Russo; J L Ho; S G Reed; W D Johnson; T C Jones
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994       Impact factor: 3.267

4.  Recombinant Leishmania major secreting biologically active granulocyte-macrophage colony-stimulating factor survives poorly in macrophages in vitro and delays disease development in mice.

Authors:  Carole Dumas; Anthony Muyombwe; Gaétan Roy; Claudine Matte; Marc Ouellette; Martin Olivier; Barbara Papadopoulou
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

5.  Contribution of non-Leishmania-specific immunity to resistance to Leishmania infection in humans.

Authors:  H O Akuffo; S F Britton
Journal:  Clin Exp Immunol       Date:  1992-01       Impact factor: 4.330

6.  Granulocyte-macrophage colony-stimulating factor (GM-CSF) reduces toxoplasmastatic activity of human monocytes via induction of prostaglandin E2 (PGE2).

Authors:  F G Delemarre; A Stevenhagen; R Van Furth
Journal:  Clin Exp Immunol       Date:  1995-11       Impact factor: 4.330

Review 7.  The role of GM-CSF in infection.

Authors:  M Freund; H D Kleine
Journal:  Infection       Date:  1992       Impact factor: 3.553

8.  Granulocyte-macrophage colony-stimulating factor increases the infectivity of Leishmania amazonensis by protecting promastigotes from heat-induced death.

Authors:  M A Barcinski; D Schechtman; L G Quintao; D de A Costa; L R Soares; M E Moreira; R Charlab
Journal:  Infect Immun       Date:  1992-09       Impact factor: 3.441

9.  Effect of granulocyte-macrophage colony-stimulating factor in experimental visceral leishmaniasis.

Authors:  H W Murray; J S Cervia; J Hariprashad; A P Taylor; M Y Stoeckle; H Hockman
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

Review 10.  Pleiotropic Effect of Hormone Insulin-Like Growth Factor-I in Immune Response and Pathogenesis in Leishmaniases.

Authors:  Luiza C Reis; Eduardo Milton Ramos-Sanchez; Fernanda N Araujo; Ariane F Leal; Christiane Y Ozaki; Orlando R Sevillano; Bernardina A Uscata; Hiro Goto
Journal:  J Immunol Res       Date:  2021-05-04       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.